Cardinal Health, Inc. 10-K Summary (Fiscal Year Ended June 30, 1999)
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended June 30, 1999, for Cardinal Health, Inc., a leading health-care service provider. The Company operates through three primary segments: Pharmaceutical Distribution, Pharmaceutical Services, and Medical-Surgical Products. The reporting period includes the retroactive consolidation of significant acquisitions, most notably Allegiance Corporation (February 1999) and R.P. Scherer Corporation (August 1998), accounted for as pooling-of-interests transactions.
Key Financial Metrics
| Metric | Fiscal 1999 | Fiscal 1998 |
|---|---|---|
| Total Revenue | $25,033.6 million | $20,995.4 million |
| Operating Revenue | $21,480.6 million | $18,004.0 million |
| Net Earnings | $456.3 million | $425.1 million |
| Diluted EPS | $1.64 | $1.53 |
| Gross Margin % | 12.03% | 12.33% |
| Operating Earnings | $877.0 million | $772.5 million |
| Net Cash from Operating Activities | $345.7 million | $552.1 million |
| Total Assets | $8,289.0 million | $7,478.0 million |
| Long-Term Obligations | $1,223.9 million | $1,330.0 million |
| Shareholders' Equity | $3,463.0 million | $2,954.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% to $25.0 billion, driven by a 25% growth in Pharmaceutical Distribution and 15% growth in Pharmaceutical Services. Approximately 82% of the increase stemmed from existing customers via volume and price increases.
- Margin Compression: Overall gross margin decreased slightly to 12.03% from 12.33%. The Pharmaceutical Distribution segment saw a decline in gross margin percentage (5.29% vs. 5.58%) due to competitive pressures and a higher mix of high-volume customers.
- Special Charges: The Company recorded $146.6 million in merger-related costs (net of tax: $117.6 million) in fiscal 1999, primarily related to the integration of Scherer and Allegiance. This compares to $57.8 million in total special charges in fiscal 1998.
- Liquidity: Working capital increased to $2.2 billion. However, cash and equivalents decreased by $208.1 million to $165.2 million, largely due to increased investments in inventory ($323.3 million) and receivables ($154.0 million) to support business volume.
Outlook, Risks, and Unusual Items
- Future Integration Costs: Management estimates an additional $100.0 million in merger-related costs will be incurred in future periods to fully integrate recent acquisitions.
- Legal Proceedings: The Company was a defendant in a class action antitrust lawsuit regarding chargeback pricing; the Court of Appeals affirmed the dismissal of the Company in July 1999, though plaintiffs filed for rehearing. Additionally, the Company assumed defense of approximately 430 lawsuits regarding natural rubber latex gloves from the Allegiance acquisition; potential liability is currently unestimable.
- Year 2000 Compliance: The Company estimates total Year 2000 project costs at $27.0 million, with approximately $20.0 million incurred to date. Management believes systems will be remediated in time to avoid material operational disruption.
- Customer Concentration: The two largest customers accounted for 11% and 13% of operating revenue in fiscal 1999. One customer accounted for 57% of bulk deliveries.
Investor Verification Checklist
- Verify the impact of the $146.6 million in merger-related charges on the reported net earnings of $456.3 million.
- Confirm the status of the pending merger with Automatic Liquid Packaging, Inc. (announced August 5, 1999) and associated regulatory approvals.
- Monitor the resolution of the natural rubber latex glove litigation assumed from Allegiance, as potential liability remains unquantified.
- Assess the sustainability of gross margins in the Pharmaceutical Distribution segment given the competitive environment and high-volume customer mix.
- Review the Company's ability to manage working capital requirements as inventory and receivables continue to grow with revenue.